All News

B CELL DEPLETION

B cell Targeting in SLE

MedPage Today

Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.

Read Article
Biomarker,genes

Where are we with Biomarkers in Rheumatoid Arthritis?

Jack Cush, MD

Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-reactive protein (CRP).

Read Article
RheumNow Podcast square

Do You Zoster Vaccinate? (6.19.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Read Article
CAR-T

CAR-T Cell Therapies at EULAR 2026

EurekAlert!

In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-citrullin

Read Article
Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

Read Article
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological https://t.co/scmfAAE9XA
Dr. John Cush RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/31IRNXckym

Links:

Dr. John Cush RheumNow ( View Tweet)
B cell Targeting in SLE Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest. https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/IFSHOM8g7w

Links:

Dr. John Cush RheumNow ( View Tweet)
From Cytokine Endotypes to Clinical Reality in Still’s Disease Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy. https://t.co/fBtkDLPJNE https://t.co/y8NBW6VHHa

Links:

Dr. John Cush RheumNow ( View Tweet)
From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/jjXrf9tcaA
Dr. John Cush RheumNow ( View Tweet)
How many CAR-T’s do we need to test drive? There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions. https://t.co/dGpfffaubX https://t.co/3MS1ZjQExj

Links:

Dr. John Cush RheumNow ( View Tweet)
Usual testing for SSA (Ro) pos. in Sjogrens identifies both Ro52 + Ro60 Abs, found in 70% of SjD. Pts who are double pos (Ro52+Ro60) have more severe dz, more Bcell activity. Ro60+ have milder dz; Recent report shows SjD pts have Ro60-specific CD4 T cells, activating Bcells https://t.co/SqoLICHOkS
Dr. John Cush RheumNow ( View Tweet)
From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg
Dr. John Cush RheumNow ( View Tweet)
How many CAR-T’s do we need to test drive? There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions. https://t.co/FvnqmKSMT4 https://t.co/Qosum9s1UX

Links:

Dr. John Cush RheumNow ( View Tweet)
CAR-T Topic Panel: EULAR 2026 Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T, from emerging data and treatment strategies to real-world challenges in diagnosis and management. https://t.co/cEOgxNYOXP https://t.co/EUpY9CLL6A

Links:

Dr. John Cush RheumNow ( View Tweet)
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route. https://t.co/8eZyDxL7wu https://t.co/Nvbj1NQb5A

Links:

Dr. John Cush RheumNow ( View Tweet)
Obinutuzumab drives histologic remission in lupus nephritis At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/13HY1qIDcj
Dr. John Cush RheumNow ( View Tweet)
Immune Dimming or Immune Reset in RA: How Far Should We Go? CD19 CAR T-cell therapy has moved from oncology to autoimmune disease after SLE reports of sustained drug-free remission suggesting an immune reset. This raises whether profound depletion is needed or if milder https://t.co/WONQmhs86j
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×